NANJING, China, Aug. 17 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE:SCR), a leading manufacturer and supplier of branded generic and innovative...
NANJING, China, Aug. 5 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE:SCR), a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in China...
NANJING, China, April 22 /Xinhua-PRNewswire Simcere Pharmaceutical Group (NYSE: SCR; 'Simcere'), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the...
Acquisition Strengthens Simcere's Leading Position in Oncology Sales, R&D and Production NANJING, China, Nov. 26 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group ('Simcere'; NYSE: SCR), a...
Transaction Strengthens Simcere's Leading Position in China's Stroke Management Market NANJING, China, Sept. 28 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR; "Simcere"), the...
NEW YORK, April 23 /PRNewswire-FirstCall/ -- The Bank of New York, a global leader in securities servicing, has been selected by Simcere Pharmaceutical Group as the depositary bank for its Level...
NANJING, China, April 19 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals in the rapidly growing China market, announced...
Notifiable Interest in Shares Securicor plc has been informed by Standard Life Investments that it no longer holds a notifiable interest in Securicor's share capital. 27 January 2004 END
RNS Number:7147T Securicor PLC 30 December 2003 BLOCKLISTING SIX MONTHLY REVIEW 1. NAME OF COMPANY: SECURICOR PLC 2. NAME OF SCHEME: SECURICOR EXECUTIVE SHARE OPTION SCHEME...
SCHEDULE 10 NOTIFICATION OF MAJOR INTERESTS IN SHARES All relevant boxes should be completed in block capital letters. 1. Name of company 2. Name of shareholder having a major interest SECURICOR...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales